Jaguar Animal Health, Inc. (NASDAQ:JAGX – Get Free Report) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 140,557 shares, an increase of 67.0% from the September 30th total of 84,156 shares. Currently, 40.7% of the shares of the stock are sold short. Based on an average daily volume of 4,969,953 shares, the short-interest ratio is presently 0.0 days.
Jaguar Animal Health Stock Performance
Jaguar Animal Health stock opened at $0.56 on Wednesday. The business has a 50 day moving average of $5.96 and a 200-day moving average of $119.34. The company has a market capitalization of $1.08 million, a P/E ratio of -0.00 and a beta of -0.09. Jaguar Animal Health has a 1 year low of $0.51 and a 1 year high of $1,102.50. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.69 and a quick ratio of 0.40.
Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($782.25) by $766.55. The business had revenue of $1.23 million during the quarter, compared to analyst estimates of $4.24 million.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on JAGX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, October 15th. Wall Street Zen raised Jaguar Animal Health to a “sell” rating in a report on Saturday, October 10th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company presently has a consensus rating of “Sell”.
Jaguar Animal Health Company Profile
Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and commercializing plant-based pharmaceuticals for gastrointestinal disorders in animals. Its research programs are designed to address conditions affecting companion animals, livestock and other animal species, with an emphasis on therapies that support intestinal function and overall animal health.
The company’s lead product is Canalevia-CA1, a prescription product containing crofelemer. Canalevia-CA1 received conditional approval from the U.S.
See Also
- Five stocks we like better than Jaguar Animal Health
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
